Figures computed from official regulatory filings — .
Analysttarget 4.6 USD (+280%) · consensus 4.57/5 · 6 buy · 1 hold · 0 sell
Ownershipinsiders 0.89% · institutions 84.7% · short 5.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ALX ONCOLOGY HOLDINGS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
22 buys188 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Lettmann Jasontrack record | Sell | $4.3K | SEC |
| Pinto Shelly | Sell | $1.1K | SEC |
| Pinto Shelly | Sell | $2.9K | SEC |
| Knight Jeff E. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klencke Barbaratrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pinto Shelly | Sell | $2K | SEC |
| Lettmann Jasontrack record | Sell | $26.7K | SEC |
| Klencke Barbaratrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pinto Shelly | Sell | $1.3K | SEC |
| Lettmann Jasontrack record | Other | $5K | SEC |
| GOODMAN COREY S | Buy | $5M | conv 56First in 12mo | SEC |
| Lettmann Jasontrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shantharam Harish | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pinto Shelly | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Curran Daniel J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hemrajani Rekha | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Takimoto Chris H | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sandler Alan B. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GOODMAN COREY S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garland J. Scott | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pinto Shelly | Sell | $4.4K | SEC |
| Pinto Shelly | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shantharam Harish | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lettmann Jasontrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klencke Barbaratrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |